Description

Brentuximab vedotin solution is the solution form of Brentuximab vedotin (HY-P99107). Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE)[1].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19.-CASNumber-914088-09-8-MolecularWeight-153000 (average)-Compound Purity-99.23-SMILES-[Brentuximab vedotin (solution)]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Apoptosis-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Apoptosis-MCE Product type-ADC Related